AdipoGen Life Sciences

What we do:
Offspring Biosciences provides contract research services to the Pharma and Biotech industry, using advanced histopathology-based analytical techniques.

Who we are
The company is managed by Anders Ericsson-Dahlstrand, Dan Sunnemark and Anne Svensson, former senior scientists at AstraZeneca's now closed R&D unit in Södertälje, Sweden. We bring extensive and solid experience supporting drug discovery teams targeting neurodegenerative diseases (Alzheimers, Parkinsons and Huntingtons disease), diabetes and oncology, with highly informative and reliable data for critical Stop/Go decisions.

Our services
- Full study deliveries (design, execution, analyses and reporting)
- Target validation studies in tissues from pre-clinical disease models
and in human tissue
- Profiling of drug binding properties, including demonstrating target engagement and performing tissue cross reactivity analyses
- Evaluating effects in pre-clinical drug treatment studies
- Evaluating side effect risks
- Supporting translational research activites
- Animal and human tissue sourcing, validation and characterization
- Crititical review of literature data regarding quality, gap and risk
- Extended services via strategic collaborations (eg tissue banking, in vivo pharmacology, bioanalysis, radiochemistry, whole body autoradiography, human and veterinary pathology)

- Right Target
- Right Drug
- Right Efficacy
- Right Safety

For further information, please visit our website
www.offspringbiosciences.se

or contact us at:

contact@offspringbiosciences.se

F-star is a leading clinical-stage biopharmaceutical company delivering tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the Company’s goal is to offer patients with cancer greater and more durable benefits than current immuno-oncology treatments. Through its proprietary tetravalent, bispecific antibody (mAb²™) format, F-star is generating best-in-class drug candidates with broad therapeutic index and monoclonal antibody-like manufacturability. Building on the combined expertise of its world-class management team and scientific leadership, F-star is poised to deliver the next breakthrough immunotherapies for patients with cancer.

Ablynx, a Sanofi company, is engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Nanobodies have potential uses in the treatment of a range of serious and life-threatening human diseases. Ablynx advances a portfolio of Nanobody-based therapeutic programs in several major disease areas, including inflammation, haematology, immuno-oncology and oncology.

The acquisition of Ablynx (June 2018) continues Sanofi’s commitment to breakthrough innovation, focused on technologies addressing multiple disease targets with single multi-specific molecules. Sanofi is committed to accelerating Ablynx’s Nanobody development programmes.

Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors. The small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib/IIa for treatment of multiple myeloma. Laquinimod is advancing to a clinical phase I study with a topical ophthalmic formulation, to be followed by phase II for treatment of non-infectious uveitis. Please visit www.activebiotech.com for more information.

Adaltis S.r.l. is an international IVD company headquartered in Rome, Italy.

Adaltis develops, manufactures and markets in-vitro diagnostic systems and reagents to detect viral infections, diagnose immune system diseases and measure human hormone responses.

http://www.adaltis.net/products/

Personal LAB - fully automated 2 plate microELISA/IFA analyser
NEXgen - fully automated 7 plate microELISA / IFA analyser
EXTRAlab - Robotic systems for liquid handling, extraction/purification of nucleic acids
Pchem Family - clinical chemistry systems for 120-500 tests/hour
(Instruments and dedicated reagents).
HEMO One - Point of Care Analyser (Diabetes / Vitamin deficiencies / Metabolic disorders / Inflammatory diseases)

With more than 10 thousands of instruments installed worldwide, Adaltis is known for excellence in performance and innovation.

Adaltis’ development and production of reagents include a wide range of assays:
- Diagnostic kits for detection of infection agents by real-time PCR (MOLgen Line)
- MicroELISA kits (EIAgen)
- Clinical Chemistry / Turbidity / Latex (CHEMgen)
- Genomics & Bioinformatics

MDx kits and reagents for DNA/RNA complete extraction kits providing a wide range of clinical specimens (liquids, tissue, cells etc.), compatible with most DNA extraction kits on market.

Adaltis provides:
Dedicated Customized Services and Antibody Production.
Adaltis has a strong record in OEM / ODM development and production of systems and kits. Well known partners have experienced and enjoy the expertise and quality products of Adaltis.

Adaltis is ISO 9001 and ISO 13485 certified. Our products are IVD-CE marked.

All of our products are backed by dedicated application support and technical service.

Customer Care Center:
info@adaltis.net

Sales and Marketing Office:
sales@adaltis.net

Order Handling and Logistics:
order@adaltis.net

Tel: + 39 0774 5791